dupilumab
regeneron,sanofi
['dupixent', 'dupilumab', '$sny']
$sny new article : press release: dupixent (dupilumab) late-breaking phase 3 data at eadv 2022 showed significant improvements in signs and symptoms of prurigo nodularis get all the latest $sny related news here : 
We’ll make staying up-to-date on top of your investments easy for you. Create a free account and get real-time financial news updates for your portfolio!